Journal of Clinical Oncology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Effect of chemotherapy with docetaxel With androgen suppression and radiotherapy for localized high-risk prostate cancer: The randomized phase III NRG Oncology RTOG 0521 Trial.
37:1159-1168.
2019
-
Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
36:667-673.
2018
-
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer.
36:841-849.
2018
-
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.
35:1929-1937.
2017
-
Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer.
35:3097-3104.
2017
-
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
35:3591-3600.
2017
-
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
35:3815-3822.
2017
-
Body mass index is prognostic in metastatic colorectal cancer: Pooled analysis of patients from first-line clinical trials in the ARCAD database.
34:144-150.
2016
-
Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib.
34:871-878.
2016
-
Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial.
34:2728-2735.
2016
-
Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma.
33:2472-2480.
2015
-
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database.
33:22-28+.
2015
-
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.
33:2609-2616.
2015
-
Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAF V600 -mutant melanoma experiencing progression with single-agent BRAF inhibitor.
32:3697-3704.
2014
-
Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: A systematic review.
31:3957-3963.
2013
-
BRAF inhibitor-driven tumor proliferation in akras-mutated colon carcinoma is not overcome by mek1/2 inhibition.
31:e448-e451.
2013
-
Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study.
31:3935-3943.
2013
-
Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer.
30:1857-1863.
2012
-
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group.
30:2654-2663.
2012
-
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
30:2119-2127.
2012
-
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
30:3596-3603.
2012
-
Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review.
30:210-216.
2012
-
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
30:1505-1512.
2012
-
Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study..
29:3531.
2011
-
Total Cholesterol and Cancer Risk in a Large Prospective Study in Korea.
29:1592-1598.
2011
-
Reply to D.J. Stewart.
28:e651-e651.
2010
-
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
28:3191-3198.
2010
-
Randomized Phase II Trials: Inevitable or Inadvisable?.
28:2641-2647.
2010
-
Reporting of Time-to-Event End Points and Tracking of Failures in Randomized Trials of Radiotherapy With or Without Any Concomitant Anticancer Agent for Locally Advanced Head and Neck Cancer.
27:5965-5971.
2009
-
Androgen Deprivation Therapy and Prostate Cancer Duration.
27:e228-e228.
2009
-
Staging (18)FDG-PET in newly diagnosed small cell lung cancer (SCLC): 15-year institutional experience..
27:e19044.
2009
-
Is It Feasible and Desirable to Collect Voluntarily Quality and Outcome Data Nationally in Palliative Oncology Care?.
26:3853-3859.
2008
-
A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
7:177S-177S.
2007
-
Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination.
24:4228-4235.
2006
-
Phase II trial of vaccination with full length NY-ESO-1/IMX in patients with advanced malignant melanoma..
24:2571.
2006
-
Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer.
24:668-674.
2006
-
Neurocognitive Consequences of Risk-Adapted Therapy for Childhood Medulloblastoma.
23:5511-5519.
2005
-
Radioimmunotherapy of Prostate Cancer: Does Tumor Size Matter?.
23:4567-4569.
2005
-
The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer.
22:1420-1429.
2004
-
Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer.
20:3130-3136.
2002
-
Use of Adjuvant Chemotherapy and Radiation Therapy for Rectal Cancer Among the Elderly: A Population-Based Study.
20:2643-2650.
2002
-
Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis.
20:9-16.
2002
-
Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: A cost-effectiveness analysis.
20:9-16.
2002
-
Variations in the Use of Chemotherapy for Elderly Patients With Advanced Ovarian Cancer: A Population-Based Study.
20:173-178.
2002
-
Variations in the Use of Chemotherapy for Elderly Patients With Advanced Ovarian Cancer: A Population-Based Study.
20:173-178.
2002
-
Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial.
19:3976-3987.
2001
-
Standard Chemotherapy for Gastric Carcinoma: Is It a Myth?.
19:2765-2767.
2001
-
Increased Temperature of Malignant Urinary Bladder Tumors In Vivo: The Application of a New Method Based on a Catheter Technique.
19:676-681.
2001
-
Enhancement of Platelet Recovery After Myelosuppressive Chemotherapy by Recombinant Human Megakaryocyte Growth and Development Factor in Patients With Advanced Cancer.
18:2852-2861.
2000
-
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma.
18:158-158.
2000
-
Multicycle High-Dose Chemotherapy and Filgrastim-Mobilized Peripheral-Blood Progenitor Cells in Women With High-Risk Stage II or III Breast Cancer: Five-Year Follow-Up.
17:82-82.
1999
-
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer..
16:2181-2187.
1998
-
Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor..
16:1899-1908.
1998
-
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer..
14:1787-1797.
1996
-
Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma..
13:1073-1079.
1995
-
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy..
12:1659-1666.
1994
-
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer..
12:1561-1571.
1994
-
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts..
12:1193-1203.
1994
-
Systematic review and network meta-analysis of treatment outcomes for multiple myeloma
2017
-
Gene expression profiling of localized prostate cancer: Getting answers to the questions that really matter
2013
-
Do Randomized Acupuncture Studies in Patients With Cancer Need a Sham Acupuncture Control Arm?
2013
-
Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart
2019
-
A phase II study of docetaxel-carboplatin as first line therapy in the patients with visceral metastatic breast cancer- a Bangladesh experience
2006
-
Clinical experience of using docetaxel-cisplatin in the treatment of advanced ovarian cancer: a Bangladesh perspective
2006
-
A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.
2019
-
ABT-806 derived antibody drug conjugates (ADCs) inhibit growth of malignant mesothelioma in-vivo.
2019
-
Australian population-based study of single- versus multi-fraction palliative radiotherapy for bone metastases.
2019
-
Patient reported outcome measures (PROMs) in patients (pts) with locally advanced rectal cancer (LARC) managed with a watch and wait (W&W) approach after a clinical complete response to chemoradiotherapy (CRT).
2019
-
Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial
2018
-
A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM).
2017
-
The clinical impact of sarcopaenia on chemotherapy delivery for gastric and oesophageal cancers.
2016
-
Can neutrophil-to-lymphocyte ratio be used to identify patients with metastatic renal cell carcinoma who may gain greater benefit from cytoreductive nephrectomy?
2015
-
Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM)
2015
-
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM)
2014
-
Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
2014
-
Assessment of IL-6, IL-8, bFGF, PDGF-BB, and VEGF-A as prognostic and predictive biomarkers for anti-VEGF in metastatic colorectal cancer (mCRC).
2014
-
Correlation of PI3KCAand extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).
2014
-
Effect of pregnant sera and a pregnancy-associated metalloproteinase (PAPP-A) on melanoma in vitro and in vivo: Insights into melanoma progression during pregnancy and potential new therapeutic targets.
2014
-
Myocardial strain for detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: Results from the St. Jude lifetime cohort study.
2014
-
Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.
2014
-
ALK and ROS1 gene rearrangements detected in colorectal cancer (CRC) by fluorescence in situ hybridization (FISH)
2013
-
A phase I and biodistribution study of ABT-806i, an (111)indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806.
2013
-
A phase I imaging and pharmacodynamic trial of CS-1008 in patients (pts) with metastatic colorectal cancer (mCRC).
2013
-
Analysis of PTEN in patients with advanced colorectal cancer (CRC) receiving capecitabine alone or in combination with bevacizumab with or without mitomycin C in the phase III AGITG MAX trial
2012
-
The kinetics of the excision repair cross-complementing group-1 (ERCC1) gene in patients with colorectal cancer
2012
-
11C-choline PET scanning is more accurate than biopsy in assessment of localized prostate cancer planned for radical prostatectomy.
2012
-
Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study.
2012
-
Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC).
2011
-
Classification of the components of the MedDietScore in relation to colorectal cancer prevalence.
2011
-
Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC).
2011
-
Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs).
2011
-
Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC).
2011
-
Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
2011
-
Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer
2011
-
Adequacy of data provision and analysis in oncology phase III trials over the past 5 years.
2010
-
Antibody targeting of epithelial carcinoma-associated fibroblast activation protein blocks cellular proliferation, migration, and invasion.
2010
-
Association of Lynch syndrome and risk of invasive cervical cancer.
2010
-
Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC).
2010
-
Clinical predictors for emesis in breast cancer patients receiving anthracycline-based chemotherapy: Do Asians measure up?
2010
-
Cognitive functioning pre- and postradiotherapy (RT), chemoradiotherapy (CRT), or bioradiotherapy (BRT) in patients with locally advanced squamous cell cancer of the head and neck (LA-SCCHN).
2010
-
Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials.
2010
-
DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.
2010
-
Evaluation of inducible expression of ERCC1 as a biomarker of drug response in human colorectal cancer cell lines.
2010
-
Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors
2010
-
Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
2009
-
Neurocognitive outcomes of head and neck chemoradiotherapy: A pilot study
2009
-
Reporting of endpoints and tracking of failures in randomized trials of radiotherapy or concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer (LA-HNSCC)
2009
-
Staging (18)FDG-PET in newly diagnosed small cell lung cancer (SCLC): 15-year institutional experience
2009
-
A phase II trial of temolozomide in patients with untreated high grade oligodengroglial brain tumours
2008
-
Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
2008
-
Synergistic therapeutic activity of chimeric G250-TNF and IFNγ for the treatment of renal cell cancer
2008
-
F-18-FDG PET changes management and improves prognostic stratification in patients with colorectal cancer: results of a prospective, multi-centre study
2007
-
Multi-centre prospective assessment of accuracy and impact on management of positron emission tomography (PET) in esophageal and gastroesophageal junction cancers (EC). Australian PET Data Collection Project
2007
-
Targeted chemoradiation for metastatic colorectal cancer: A phase I trial of oral capecitabine combined with I-131-huA33
2007
-
Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab).
2006
-
Phase I study of CHP-HER2 polyvalent cancer vaccine, HER2 protein combined with a novel nanoparticle antigen delivery system of cholesteryl hydrophobized polysaccharides.
2005
-
A phase I trial of humanized monoclonal antibody huA33 in patients with early gastric cancer: Imaging studies, biodistribution, pharmacolkinetics, immunohistochemistry, and quantitative tumor uptake
2004
-
Phase I trial of hu3S193 in patients with advanced epithelial cancers which express the Lewis-y antigen.
2004
-
The utility of in-vivo functional and genetic parameters of drug elimination for the estimation of irinotecan (Ir) clearance (CL).
2004
-
Combination of CDK and Bcl-2 inhibitors in the treatment of soft-tissue sarcomas
2018
-
Sketching the Human Experience.
32:2109-2111.
2014
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)